Welcome to our dedicated page for Cadrenal Therapeutics SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cadrenal Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cadrenal Therapeutics's regulatory disclosures and financial reporting.
Cadrenal Therapeutics reported a Q1 2026 net loss of $2.5 million, narrower than $3.8 million a year earlier, as operating expenses fell 36% to $2.5 million. Cash and cash equivalents were $2.3 million with net cash used in operations of $3.0 million, raising substantial doubt about its ability to continue as a going concern.
The late-stage biopharma is prioritizing lead candidate CAD-1005 for heparin-induced thrombocytopenia and plans a Phase 3 trial targeting an NDA submission in 2029. Stockholders’ equity of $1.8 million fell below Nasdaq’s $2.5 million requirement, though a subsequent $2.5 million warrant exercise in April 2026 is expected to bolster equity.
Cadrenal Therapeutics announced that it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance for a pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia (HIT). Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
The company plans a randomized, blinded, placebo-controlled Phase 3 study in approximately 120 HIT patients across up to 50 clinical centers worldwide, with treatment for up to 14 days during hospitalization. The trial is intended to support a projected NDA submission in 2029.
Cadrenal Therapeutics, Inc. is registering 1,180,003 shares of Common Stock for resale by selling stockholders, consisting of 1,142,860 shares issuable upon exercise of Investor Warrants and 37,143 shares issuable upon exercise of Placement Agent Warrants. The company will not receive proceeds from resales but will receive proceeds from any cash exercises of those warrants.
The registration fulfills contractual registration rights under an inducement agreement related to a private placement and warrants issued April 1, 2026; resales may occur in public or private transactions at prevailing or negotiated prices.
Cadrenal Therapeutics, Inc. is registering 1,180,003 shares of Common Stock for resale by selling stockholders.
The shares consist of 1,142,860 shares issuable upon exercise of Investor Warrants and 37,143 shares issuable upon exercise of Placement Agent Warrants. The resale proceeds will go to the selling stockholders; the company will receive proceeds only from any cash exercise of the warrants. The prospectus states 3,078,247 shares were outstanding as of April 1, 2026 and assumes 4,258,250 shares outstanding after full exercise.
Cadrenal Therapeutics, Inc. entered into a warrant inducement agreement with an existing holder, who agreed to exercise warrants for up to 571,430 common shares at $4.50 per share. This cash exercise is expected to provide approximately $2.5 million in gross proceeds for working capital.
In return, Cadrenal issued new unregistered Series B-1 and Series B-2 warrants, each for 571,430 shares at an exercise price of $4.50 per share, plus placement agent warrants for 37,143 shares at $5.625 per share. The company will file a Form S-3 to register the resale of the new warrant shares and agreed to short-term restrictions on issuing additional equity or registration statements.
Cadrenal Therapeutics registered 590,001 shares of Common Stock for resale under a prospectus supplement to its Form S-3 registration statement. The supplement states that 571,430 of those shares are issuable upon exercise of Existing Warrants that were amended on March 31, 2026 to reduce the exercise price from $16.50 to $4.50. The supplement covers resale "from time to time," and the prospectus remains qualified by the underlying Form S-3 prospectus.
The company reports a Nasdaq closing price of $5.12 per share as of March 31, 2026. The supplement updates warrant terms and registers the related shares; other prospectus terms continue to apply.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic conditions. The company has shifted its primary focus to CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), supported by orphan drug and Fast Track designations.
Cadrenal recently acquired a 12-LOX asset platform from Veralox and a portfolio of Factor XIa inhibitors, including frunexian, from eXIthera, adding clinical-stage assets and associated licenses and royalty obligations. Its broader pipeline includes tecarfarin, a late-stage vitamin K antagonist for high-risk cardiovascular patients, and frunexian, an IV Factor XIa inhibitor for acute critical-care settings.
On March 26, 2026, Cadrenal completed an End-of-Phase 2 FDA meeting for CAD-1005 and clarified a potential registrational path for a planned pivotal Phase 3 HIT trial, which remains subject to final FDA meeting minutes, protocol review and securing sufficient financing.
Cadrenal Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 FDA meeting on March 26, 2026 to align on a proposed Phase 3 pivotal trial design.
For Q4 2025, research and development expenses were $0.7 million, down from $1.5 million a year earlier, while general and administrative expenses were $2.4 million, down from $2.7 million. Cadrenal posted a quarterly net loss of $3.0 million, improving from a $4.2 million loss in Q4 2024.
For the full year 2025, operating expenses totaled $13.5 million and the net loss was $13.2 million, compared with a $10.7 million net loss in 2024. Cash and cash equivalents were $4.0 million as of December 31, 2025, and the company is evaluating financing and strategic alternatives to support planned clinical development.
Cadrenal Therapeutics reported new preclinical research on its first-in-class 12-lipoxygenase inhibitor CAD-1005, showing potential to address inflammation linked to obesity and Type 2 diabetes. In animal models, oral CAD-1005 (formerly VLX-1005) improved glycemic control, reduced pancreatic β-cell loss, lowered inflammatory cells in fat and pancreatic tissue, and decreased pro-inflammatory cytokines in adipose tissue.
The findings support 12-LOX as a key driver of obesity-related inflammation and suggest that selectively inhibiting this enzyme may help restore metabolic signaling and protect tissues from inflammatory damage. CAD-1005 is already in clinical development for suspected heparin-induced thrombocytopenia (HIT), where a Phase 2 trial showed reduced thrombotic events. The company is also advancing next-generation oral 12-LOX inhibitor CAD-2000 and maintains additional late-stage programs, including the anticoagulant tecarfarin and Factor XIa inhibitor frunexian.